AR091977A1 - El uso de antitrombina en la oxigenacion de membranas extracorporeas - Google Patents
El uso de antitrombina en la oxigenacion de membranas extracorporeasInfo
- Publication number
- AR091977A1 AR091977A1 ARP130102756A ARP130102756A AR091977A1 AR 091977 A1 AR091977 A1 AR 091977A1 AR P130102756 A ARP130102756 A AR P130102756A AR P130102756 A ARP130102756 A AR P130102756A AR 091977 A1 AR091977 A1 AR 091977A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxygenation
- extracorpore
- antitrombin
- membranes
- antithrombin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Métodos para la supresión de la coagulación de la sangre y/o la prevención de la hemorragia en un sujeto que recibe oxigenación por membrana extracorpórea que comprende la administración de antitrombina. En algunas formas de realización, la antitrombina que se utiliza en los métodos descritos en el presente documente es ATryn®. Reivindicación 10: El método de una cualquiera de las reivindicaciones 1 - 8, en donde la antitrombina se administra a una dosis de 295 unidades por kg. Reivindicación 14: El método de una cualquiera de las reivindicaciones 1 - 13, que comprende además la administración de heparina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261679345P | 2012-08-03 | 2012-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091977A1 true AR091977A1 (es) | 2015-03-11 |
Family
ID=50028554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102756A AR091977A1 (es) | 2012-08-03 | 2013-08-02 | El uso de antitrombina en la oxigenacion de membranas extracorporeas |
Country Status (13)
Country | Link |
---|---|
US (1) | US9511087B2 (es) |
EP (1) | EP2879697A4 (es) |
JP (1) | JP6389172B2 (es) |
KR (1) | KR20150039201A (es) |
CN (1) | CN104884080A (es) |
AR (1) | AR091977A1 (es) |
AU (1) | AU2013296240B2 (es) |
BR (1) | BR112015002321A2 (es) |
CA (1) | CA2879763C (es) |
IL (1) | IL236776A0 (es) |
MX (1) | MX2015001508A (es) |
TW (1) | TW201425332A (es) |
WO (1) | WO2014022748A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3834851A1 (en) | 2010-12-30 | 2021-06-16 | Laboratoire Français du Fractionnement et des Biotechnologies | Glycols as pathogen inactive agents |
AR091977A1 (es) | 2012-08-03 | 2015-03-11 | Revo Biolog Inc | El uso de antitrombina en la oxigenacion de membranas extracorporeas |
CN105263319A (zh) | 2013-02-13 | 2016-01-20 | 法国化学与生物科技实验室 | 具有经修饰的糖基化的蛋白及其生产方法 |
EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
EP3388140A1 (en) * | 2017-04-10 | 2018-10-17 | Gambro Lundia AB | Extracorporeal blood circuit |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
DE4028800A1 (de) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
US5801063A (en) | 1995-05-09 | 1998-09-01 | Grandics; Peter | Device and process for the biospecific removal of heparin |
US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
WO1998037224A1 (en) | 1997-02-25 | 1998-08-27 | Genzyme Transgenics Corporation | Transgenically produced non-secreted proteins |
US20060264357A1 (en) | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
US8257724B2 (en) | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
DE10159556A1 (de) | 2001-12-05 | 2003-06-12 | Aventis Behring Gmbh Intellect | Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen |
SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
US7550263B2 (en) | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
CA2479968A1 (en) | 2004-09-01 | 2006-03-01 | Keith R. Walley | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
CA2572179A1 (en) | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
CA2612859A1 (en) | 2005-06-23 | 2006-12-28 | The University Of British Columbia | Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
WO2007014244A2 (en) | 2005-07-25 | 2007-02-01 | Gtc Biotherapeutics, Inc. | Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile |
CN101484470B (zh) | 2005-10-21 | 2014-07-23 | 阿伊沃生物制剂有限公司 | 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 |
US20070292407A1 (en) | 2005-12-12 | 2007-12-20 | The Board Of Trustees Operating Michigan State University | Methods of treatment for meconium aspiration syndrome |
US7531632B2 (en) | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
US8173860B2 (en) | 2006-04-21 | 2012-05-08 | Gtc Biotherapeutics, Inc. | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion |
WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
US20110082083A1 (en) | 2009-04-10 | 2011-04-07 | Gtc Biotherapeutics, Inc. | Formulations of liquid stable antithrombin |
US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
CA2840876A1 (en) | 2011-07-07 | 2013-01-10 | Revo Biologics, Inc. | Formulations that stabilize proteins |
TW201400499A (zh) | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
AR091977A1 (es) | 2012-08-03 | 2015-03-11 | Revo Biolog Inc | El uso de antitrombina en la oxigenacion de membranas extracorporeas |
-
2013
- 2013-08-02 AR ARP130102756A patent/AR091977A1/es unknown
- 2013-08-02 WO PCT/US2013/053365 patent/WO2014022748A1/en active Application Filing
- 2013-08-02 CN CN201380041286.1A patent/CN104884080A/zh active Pending
- 2013-08-02 MX MX2015001508A patent/MX2015001508A/es unknown
- 2013-08-02 TW TW102127828A patent/TW201425332A/zh unknown
- 2013-08-02 CA CA2879763A patent/CA2879763C/en active Active
- 2013-08-02 AU AU2013296240A patent/AU2013296240B2/en not_active Ceased
- 2013-08-02 US US14/239,943 patent/US9511087B2/en active Active
- 2013-08-02 BR BR112015002321A patent/BR112015002321A2/pt not_active IP Right Cessation
- 2013-08-02 EP EP13825397.6A patent/EP2879697A4/en not_active Withdrawn
- 2013-08-02 KR KR1020157002667A patent/KR20150039201A/ko not_active Application Discontinuation
- 2013-08-02 JP JP2015525617A patent/JP6389172B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-18 IL IL236776A patent/IL236776A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN104884080A (zh) | 2015-09-02 |
EP2879697A1 (en) | 2015-06-10 |
US20140194360A1 (en) | 2014-07-10 |
KR20150039201A (ko) | 2015-04-09 |
CA2879763A1 (en) | 2014-02-06 |
IL236776A0 (en) | 2015-03-31 |
EP2879697A4 (en) | 2016-01-20 |
TW201425332A (zh) | 2014-07-01 |
AU2013296240A1 (en) | 2015-02-12 |
JP2015524823A (ja) | 2015-08-27 |
AU2013296240B2 (en) | 2018-05-17 |
US9511087B2 (en) | 2016-12-06 |
WO2014022748A1 (en) | 2014-02-06 |
JP6389172B2 (ja) | 2018-09-12 |
BR112015002321A2 (pt) | 2019-10-22 |
MX2015001508A (es) | 2015-04-08 |
CA2879763C (en) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091977A1 (es) | El uso de antitrombina en la oxigenacion de membranas extracorporeas | |
MX2021001867A (es) | Administracion y monitoreo de oxidio nitrico en fluidos ex vivo. | |
BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
CR20170279A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2012003038A1 (es) | Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia. | |
BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
CO7190239A2 (es) | Dialisato a base de polímero | |
PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
BR112016010103A8 (pt) | métodos, kits e dispositivos de suprimento de fármaco osmótico. | |
DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
CL2015002747A1 (es) | Metodo para la oxigenacion extracorporea de un sujeto; y aparato de incubacion. | |
CL2013001382A1 (es) | Metodo para aumentar la seguridad y la eficacia de las transfusiones de sangre, que comprende administrar a un paciente una composicion farmaceutica que comprende un copolimero de polioxietileno/polioxipropileno, en donde la composicion se mezcla con la sangre antes de la transfusion, o se administra al paciente antes o despues de la transfusion. | |
BR112016026243A2 (pt) | membrana, molécula de fibra oca, uso de uma membrana, e, copolímero em bloco | |
GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
ECSP10010553A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
DOP2015000175A (es) | Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular | |
CL2015001943A1 (es) | Derivados de bencilamina | |
UA112488C2 (uk) | Три(гетеро)арилпіразоли і їх застосування | |
ES2972414T3 (es) | Cánula arterial bidireccional para oxigenación por membrana extracorpórea y procedimiento de uso de dicha cánula | |
BR112014005221A2 (pt) | uso de materiais de fibra oca modificada para a remoção de exotoxinas produzidas por escherichia coli a partir de liquidos, de preferência a partir de sangue e de plasma, bem como seu uso para o tratamento de doenças concomitantes | |
AR105503A1 (es) | Concentrado que contiene alprostadil | |
CO6670569A2 (es) | Agentes anti-inflamatorios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |